Singapore, Nov. 28 -- SK Biopharmaceuticals, a South Korea-based biotech company specialising in research, development, and commercialisation of treatments for central nervous system (CNS) disorders and oncology, has announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights for research and development (R&D), manufacturing, and commercialisation of WARF's "WT-7695," a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the University of Wisconsin-Madison, US.

This agreement represents SK Biopharmaceuticals' second in-licensed asset in the radiopharmaceutical therapy field, following its first asset "SKL35501 (formerly FL-091)" in 2024. ...